Keymed Biosciences Inc. (HKG:2162)

Keymed Biosciences Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 11, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	16,453	8,516	13,586	14,174	9,651	-
Market Cap Growth	49.25%	-37.32%	-4.15%	46.87%	-	-
Enterprise Value	14,346	6,526	10,725	10,331	15,170	-
Last Close Price	55.85	30.90	49.10	51.00	34.50	-
PS Ratio	17.22	18.69	34.83	125.30	71.30	-
PB Ratio	4.70	3.23	4.13	3.76	2.16	-
P/TBV Ratio	4.71	3.25	4.13	3.76	2.15	-
EV/Sales Ratio	15.01	14.32	27.49	91.33	112.08	-
Debt / Equity Ratio	0.27	0.30	0.14	0.04	0.01	-1.33
Asset Turnover	0.21	0.11	0.09	0.03	0.05	-
Inventory Turnover	0.32	0.13	0.66	0.07	1.02	-
Quick Ratio	3.66	3.04	8.80	8.45	31.55	4.42
Current Ratio	3.95	3.30	9.36	8.72	31.96	4.75
Return on Equity (ROE)	-8.82%	-18.85%	-11.31%	-8.69%	-305.24%	-
Return on Assets (ROA)	-5.44%	-10.23%	-7.32%	-8.65%	-10.09%	-15.67%
Return on Capital (ROIC)	-6.17%	-11.80%	-8.33%	-9.52%	-11.15%	-20.89%
Return on Capital Employed (ROCE)	-9.60%	-20.70%	-12.80%	-15.30%	-9.40%	-33.10%
Earnings Yield	-1.71%	-6.44%	-2.91%	-2.46%	-49.44%	-
FCF Yield	-5.69%	-12.46%	-5.53%	-5.43%	-4.92%	-
Buyback Yield / Dilution	-0.70%	-0.22%	-0.09%	-62.34%	-139.72%	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.